61 related articles for article (PubMed ID: 12796362)
1. Two molecular subgroups of Wilms' tumors with or without WT1 mutations.
Schumacher V; Schuhen S; Sonner S; Weirich A; Leuschner I; Harms D; Licht J; Roberts S; Royer-Pokora B
Clin Cancer Res; 2003 Jun; 9(6):2005-14. PubMed ID: 12796362
[TBL] [Abstract][Full Text] [Related]
2. WT1-Mutant Wilms Tumor Progression Is Associated With Diverting Clonal Mutations of CTNNB1.
Duhme C; Busch M; Heine E; de Torres C; Mora J; Royer-Pokora B
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e180-e183. PubMed ID: 31876779
[TBL] [Abstract][Full Text] [Related]
3. Gene expression studies of WT1 mutant Wilms tumor cell lines in the frame work of published kidney development data reveals their early kidney stem cell origin.
Royer-Pokora B; Wruck W; Adjaye J; Beier M
PLoS One; 2023; 18(1):e0270380. PubMed ID: 36689432
[TBL] [Abstract][Full Text] [Related]
4. Wilms Tumor: An Unexpected Diagnosis in Adult Patients.
Chan GJ; Stohr BA; Osunkoya AO; Croom NA; Cho SJ; Balassanian R; Charu V; Bean GR; Chan E
Arch Pathol Lab Med; 2024 Jun; 148(6):722-727. PubMed ID: 37756569
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Alternative Splicing in High-Risk Wilms' Tumors.
Trink Y; Urbach A; Dekel B; Hohenstein P; Goldberger J; Kalisky T
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674106
[TBL] [Abstract][Full Text] [Related]
6. Gene expression analysis and the risk of relapse in favorable histology Wilms' tumor.
Abdel-Monem MM; El-Khawaga OY; Awadalla AA; Hafez AT; Ahmed AE; Abdelhameed M; Abdelhalim A
Arab J Urol; 2023; 21(1):45-51. PubMed ID: 36818371
[TBL] [Abstract][Full Text] [Related]
7. Long-term kidney function in children with Wilms tumour and constitutional WT1 pathogenic variant.
Falcone MP; Pritchard-Jones K; Brok J; Mifsud W; Williams RD; Nakata K; Tugnait S; Al-Saadi R; Side L; Anderson J; Duncan C; Marks SD; Bockenhauer D; Chowdhury T
Pediatr Nephrol; 2022 Apr; 37(4):821-832. PubMed ID: 34608521
[TBL] [Abstract][Full Text] [Related]
8. Stromal-like Wilms tumor cells induce human Natural Killer cell degranulation and display immunomodulatory properties towards NK cells.
Cantoni C; Serra M; Parisi E; Azzarone B; Sementa AR; Nasto LA; Moretta L; Candiano G; Bottino C; Ghiggeri GM; Spaggiari GM
Oncoimmunology; 2021 Mar; 10(1):1879530. PubMed ID: 33758675
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy and terminal skeletal muscle differentiation in WT1-mutant Wilms tumors.
Royer-Pokora B; Beier M; Brandt A; Duhme C; Busch M; de Torres C; Royer HD; Mora J
Cancer Med; 2018 Apr; 7(4):1359-1368. PubMed ID: 29542868
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic utility of Wilms' tumour-1 protein (WT-1) immunostaining in paediatric renal tumours.
Goyal S; Mishra K; Sarkar U; Sharma S; Kumari A
Indian J Med Res; 2016 May; 143(Supplement):S59-S67. PubMed ID: 27748279
[TBL] [Abstract][Full Text] [Related]
11. Establishment of a Conditionally Immortalized Wilms Tumor Cell Line with a Homozygous WT1 Deletion within a Heterozygous 11p13 Deletion and UPD Limited to 11p15.
Brandt A; Löhers K; Beier M; Leube B; de Torres C; Mora J; Arora P; Jat PS; Royer-Pokora B
PLoS One; 2016; 11(5):e0155561. PubMed ID: 27213811
[TBL] [Abstract][Full Text] [Related]
12. Energy metabolism in neuroblastoma and Wilms tumor.
Aminzadeh S; Vidali S; Sperl W; Kofler B; Feichtinger RG
Transl Pediatr; 2015 Jan; 4(1):20-32. PubMed ID: 26835356
[TBL] [Abstract][Full Text] [Related]
13. Deducing the stage of origin of Wilms' tumours from a developmental series of Wt1-mutant mice.
Berry RL; Ozdemir DD; Aronow B; Lindström NO; Dudnakova T; Thornburn A; Perry P; Baldock R; Armit C; Joshi A; Jeanpierre C; Shan J; Vainio S; Baily J; Brownstein D; Davies J; Hastie ND; Hohenstein P
Dis Model Mech; 2015 Aug; 8(8):903-17. PubMed ID: 26035382
[TBL] [Abstract][Full Text] [Related]
14. The yin and yang of kidney development and Wilms' tumors.
Hohenstein P; Pritchard-Jones K; Charlton J
Genes Dev; 2015 Mar; 29(5):467-82. PubMed ID: 25737276
[TBL] [Abstract][Full Text] [Related]
15. Classification of a frameshift/extended and a stop mutation in WT1 as gain-of-function mutations that activate cell cycle genes and promote Wilms tumour cell proliferation.
Busch M; Schwindt H; Brandt A; Beier M; Görldt N; Romaniuk P; Toska E; Roberts S; Royer HD; Royer-Pokora B
Hum Mol Genet; 2014 Aug; 23(15):3958-74. PubMed ID: 24619359
[TBL] [Abstract][Full Text] [Related]
16. Is Wilms tumor a candidate neoplasia for treatment with WNT/β-catenin pathway modulators?--A report from the renal tumors biology-driven drug development workshop.
Perotti D; Hohenstein P; Bongarzone I; Maschietto M; Weeks M; Radice P; Pritchard-Jones K
Mol Cancer Ther; 2013 Dec; 12(12):2619-27. PubMed ID: 24258344
[TBL] [Abstract][Full Text] [Related]
17. Loss of heterozygosity at 11p13 and 11p15 in Wilms tumor: a study of 22 cases from India.
Sigamani E; Wari MN; Iyer VK; Agarwala S; Sharma A; Bakhshi S; Dinda A
Pediatr Surg Int; 2013 Mar; 29(3):223-7. PubMed ID: 23292539
[TBL] [Abstract][Full Text] [Related]
18. Acute multiple organ failure in adult mice deleted for the developmental regulator Wt1.
Chau YY; Brownstein D; Mjoseng H; Lee WC; Buza-Vidas N; Nerlov C; Jacobsen SE; Perry P; Berry R; Thornburn A; Sexton D; Morton N; Hohenstein P; Freyer E; Samuel K; van't Hof R; Hastie N
PLoS Genet; 2011 Dec; 7(12):e1002404. PubMed ID: 22216009
[TBL] [Abstract][Full Text] [Related]
19. WT1-dependent sulfatase expression maintains the normal glomerular filtration barrier.
Schumacher VA; Schlötzer-Schrehardt U; Karumanchi SA; Shi X; Zaia J; Jeruschke S; Zhang D; Pavenstädt H; Drenckhan A; Amann K; Ng C; Hartwig S; Ng KH; Ho J; Kreidberg JA; Taglienti M; Royer-Pokora B; Ai X
J Am Soc Nephrol; 2011 Jul; 22(7):1286-96. PubMed ID: 21719793
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
